Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer

NCT06757244 is registered in ClinicalTrials.gov with Hopital Foch as lead sponsor.

NCT NCT06757244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06757244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer
Lead sponsor
Hopital Foch
Phase
Phase 2
Overall status
Recruiting
Start date
February 18, 2025
Completion date
February 18, 2028
Enrollment
35 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas neoplasms